nach oben

Journal of Neuro-Oncology

Erschienen in:

01.07.2009 | Case report

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

verfasst von: Roy Torcuator, Richard Zuniga, Randa Loutfi, Tom Mikkelsen

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.

Packer RJ (1999) Brain tumors in children. Arch Neurol 56(4):421–425. doi:10.1001/archneur.56.4.421 PubMedCrossRef

Freeman CR, Farmer JP (1998) Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40(2):265–271. doi:10.1016/S0360-3016(97)00572-5 PubMed

Rubin G, Michowitz S, Horev G, Herscovici Z, Cohen IJ, Shuper A, Rappaport ZH (1998) Pediatric brain stem gliomas: an update. Childs Nerv Syst 14(4–5):167–173. doi:10.1007/s003810050205 PubMedCrossRef

Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P, Haie-Meder C, Defer GL, Maison P, Mazeron JJ, Cornu P, Delattre JY, Association des Neuro-Oncoloques d’Expression Francoise (ANOCEF) (2001) Brainstem gliomas in adults: prognostic factors and classification. Brain 124(Pt 12):2528–2539. doi:10.1093/brain/124.12.2528 PubMedCrossRef

Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, Giombini S, Poggi G, Pecori E, Pignoli E, Casanova M, Ferrari A, Meazza C, Luksch R, Terenziam M, Cefalo G, Podda M, Polastri D, Clerici CA, Fossati-Bellani F, Gondola L (2008) Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 87(3):355–361. doi:10.1007/s11060-008-9525-5 PubMedCrossRef

Landolfi JC, Thaler HT, DeAngelis LM (1998) Adult brainstem gliomas. Neurology 51(4):1136–1139PubMed

Selvapandian S, Rajshekhar V, Chandy MJ (1999) Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 141(7):721–726. doi:10.1007/s007010050367 (discussion 726–727)CrossRef

Epstein F, Constantini S (1996) Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 24(1):24–34. doi:10.1159/000121011 PubMedCrossRef

Schild SE, Stafford SL, Brown PD, Wood CP, Scheithauer BW, Schombert PJ, Wong WW, Lyons MK, Shaw EG (1998) The results of radiotherapy for brainstem tumors. J Neurooncol 40(2):171–177. doi:10.1023/A:1006193306286 PubMedCrossRef

10.

Freeman CR, Perilongo G (1999) Chemotherapy for brain stem gliomas. Childs Nerv Syst 15(10):545–553. doi:10.1007/s003810050542 PubMedCrossRef

11.

Shuper A, Kornreich L, Loven D, Michowitz S, Schwartz M, Cohen IJ (1998) Diffuse brain stem gliomas. Are we improving outcome? Childs Nerv Syst 14(10):578–581. doi:10.1007/s003810050275 PubMedCrossRef

12.

Bouffet E, Khelfaoui F, Philip I, Biron P, Brunet-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39(4):376–379. doi:10.1007/s002800050586 PubMedCrossRef

13.

Allen JC, Siffert J (1996) Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 24(2):98–102. doi:10.1159/000121024 PubMedCrossRef

14.

Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, Kuehl J (2002) Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87(9):945–949. doi:10.1038/sj.bjc.6600552 PubMedCrossRef

15.

Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259. doi:10.1158/1078-0432.CCR-06-2309 PubMedCrossRef

16.

Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathosumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729. doi:10.1200/JCO.2007.12.2440 PubMedCrossRef

17.

Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, hiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s (abstr 2010b)

18.

Gururangan S, Chi S, Onar A, Packer R, Young Poussaint T, Gilbertson R, Friedman H, Kun L, Boyett J (2008) Phase II study of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma—a Pediatric Brain Consortium Study (PBTC-022). Neuro Oncol 5:833 (abstract MA-63)

19.

Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206. doi:10.1634/theoncologist.9-2-197 PubMedCrossRef

20.

Lu C, Shervington A (2008) Chemoresistance in gliomas. Mol Cell Biochem 312:71–80. doi:10.1007/s11010-008-9722-8 PubMedCrossRef

21.

Reddy A, Mapstone T (2000) Brain stem tumors. In: Bernstein M, Berger MS (eds) Neuro-oncology the essentials. Thieme Medical Publishers, Inc, New York, pp 352–386

22.

Packer RJ, Prados M, Phillips P, Nicholson HS, Bovett JM, Goldwein J, Rorke LB, Needle MN, Sutton L, Zimmerman RA, Fitz CR, Vezina LG, Etcubanas E, Wallenberg JC, Reaman G, Wara W (1996) Treatment of children with newly diagnosed brainstem gliomas with intravenous recombinant beta-inteferon and hyperfractionated radiation therapy: a Childrens Cancer Group phase I/II study. Cancer 77:2150–2156. doi:10.1002/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-TPubMedCrossRef

23.

Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goulmnerova L, Billett AL, Kieran M, Tarbell NJ (2003) A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 55(5):1182–1185. doi:10.1016/S0360-3016(02)04391-2 PubMed

24.

Findlay JL, Zacharoulis S (2005) The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical- and futuristic-perspective. J Neurooncol 75:253–266. doi:10.1007/s11060-005-6747-7 CrossRef

25.

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumors. Nat Rev Neurosci 8(8):610–622. doi:10.1038/nrn2175 PubMedCrossRef

26.

Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(4(Suppl 3)):7–16 (Williston Park)PubMed

Titel: Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report
verfasst von: Roy Torcuator
Richard Zuniga
Randa Loutfi
Tom Mikkelsen
Publikationsdatum: 01.07.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9782-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Germ cell tumors of the brainstem: report on two cases with pulmonary complications and a review of the literature

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients

Multiple intracranial melanoma metastases: case report and review of the literature

Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction

No-glucose strategy influences posterior cranial fossa tumors' postoperative course: introducing the Glycemic Stress Index

Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Update Neurologie